Mechanisms of resistance to hormonal treatment in breast cancer

被引：12
作者：
Eroles, Pilar [2 ]
Bosch, Ana [2 ]
Bermejo, Begona [1 ]
Lluch, Ana [1 ,2 ]
机构：
[1] Hosp Clin Univ Valencia, Serv Hematol & Oncol Med, ES-46010 Valencia, Spain
[2] Hosp Clin Univ Valencia, Fdn Invest, ES-46010 Valencia, Spain
来源：
CLINICAL & TRANSLATIONAL ONCOLOGY | 2010年 / 12卷 / 04期
关键词：
Breast cancer; Hormonal treatment; Resistance; CYPD2D6; TK inhibitors; AIB1; PAX2; ESTROGEN-RECEPTOR-ALPHA; ENDOCRINE-THERAPY RESISTANCE; NITRIC-OXIDE SYNTHASE; TAMOXIFEN RESISTANCE; PHASE-II; CYP2D6; GENOTYPE; CROSS-TALK; N-COR; EXPRESSION; ACTIVATION;
D O I：
10.1007/s12094-010-0500-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Endocrine therapy is a cornerstone in hormone-dependent breast cancer treatment. Despite the effectiveness of this type of treatment, a significant percentage of tumours develop resistance, and hence, patients relapse. This raises the question of which mechanisms are activated by hormone-dependent tumours to become resistant to antihormonal therapy. The aim of this review is to summarise the current knowledge on structure and mechanisms of action of oestrogen receptors and the possible mechanisms of resistance known to date, focusing on the existing crosstalk between oestrogen receptor and growth factor receptor pathways as well as the influence of drug metabolism in its effectiveness. Finally, the clinical evidence of hormonal therapy resistance and the future directions for optimising breast cancer treatment is also discussed.
引用
收藏
页码：246 / 252
页数：7
相关论文
共 63 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance [J].
Atanaskova, N ;
Keshamouni, VG ;
Krueger, JS ;
Schwartz, JA ;
Miller, F ;
Reddy, KB .
ONCOGENE, 2002, 21 (25) :4000-4008
[3]   Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer [J].
Baselga, Jose ;
Semiglazov, Vladimir ;
van Dam, Peter ;
Manikhas, Alexey ;
Bellet, Meritxell ;
Mayordomo, Jose ;
Campone, Mario ;
Kubista, Ernst ;
Greil, Richard ;
Bianchi, Giulia ;
Steinseifer, Jutta ;
Molloy, Betty ;
Tokaji, Erika ;
Gardner, Humphrey ;
Phillips, Penny ;
Stumm, Michael ;
Lane, Heidi A. ;
Dixon, J. Michael ;
Jonat, Walter ;
Rugo, Hope S. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2630-2637
[4]  
Beatson GT., 1896, LANCET, V148, P104
[5]   Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment [J].
Borges, Silvana ;
Desta, Zeruesenay ;
Li, Lang ;
Skaar, Todd C. ;
Ward, Bryan A. ;
Nguyen, Anne ;
Jin, Yan ;
Storniolo, Anna Maria ;
Nikoloff, D. Michele ;
Wu, Lin ;
Hillman, Grant ;
Hayes, Daniel F. ;
Stearns, Vered ;
Flockhart, David A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (01) :61-74
[6]   CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants [J].
Bradford, LD .
PHARMACOGENOMICS, 2002, 3 (02) :229-243
[7]   Estrogen receptor α mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen [J].
Chen, Z ;
Yuhanna, IS ;
Galcheva-Gargova, Z ;
Karas, RH ;
Mendelsohn, RE ;
Shaul, PW .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (03) :401-406
[8]   Drug approval summaries: Arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene [J].
Cohen, MH ;
Hirschfeld, S ;
Honig, SF ;
Ibrahim, A ;
Johnson, JR ;
O'Leary, JJ ;
White, RM ;
Williams, GA ;
Pazdur, R .
ONCOLOGIST, 2001, 6 (01) :4-11
[9]  
CRISTOFANILLIN M, 2008, ASCO M
[10]   AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor [J].
de Mora, JF ;
Brown, M .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (14) :5041-5047
1234567